The SLC7A5 antibody is a polyclonal rabbit IgG antibody designed to detect the SLC7A5 protein, which forms a heterodimer with SLC3A2 to transport large neutral amino acids (e.g., leucine, phenylalanine) . This antibody is widely used in research to investigate SLC7A5's roles in nutrient sensing, mTORC1 signaling, and disease mechanisms .
Triple-Negative Breast Cancer (TNBC):
SLC7A5 is overexpressed in TNBC and correlates with poor prognosis. Knockdown or inhibition (e.g., via JPH203) reduces tumor proliferation, migration, and metastasis by disrupting glutamine metabolism and mTORC1 signaling . Combining SLC7A5 blockade with anti-PD-1 immunotherapy synergistically enhances antitumor efficacy and CD8+ T-cell infiltration .
Mechanistic Insights:
Inflammatory Diseases:
SLC7A5 is upregulated in monocytes/macrophages during inflammation (e.g., rheumatoid arthritis). Its inhibition decreases IL-1β production by impairing leucine-dependent mTORC1 activation and glycolysis .
Red Blood Cell Maturation:
Slc7a5 deficiency in mice causes smaller red blood cells with reduced hemoglobin, highlighting its role in reticulocyte maturation and mitochondrial activity .
| Parameter | High SLC7A5 vs. Low SLC7A5 |
|---|---|
| 5-Year OS | 45% vs. 72% (P = 0.020) |
| 5-Year DFS | 38% vs. 65% (P = 0.041) |
| Lung Metastasis Incidence | 2.5-fold higher |